Abstracts tagged "interstitial lung disease"

Abstract Number: 2141 • 2019 ACR/ARP Annual Meeting
Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients
Kristin D'Silva¹, Marcy Bolster ¹, Flavia Castelino ², Amita Sharma ¹, Brent Little ¹, Sydney Montesi ¹ and Hyon K. Choi ¹, ¹Massachusetts General Hospital, Boston, MA, ²Harvard University, Boston, MA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in patients with connective tissue diseases (CTD). Approximately one-third of patients with…
Abstract Number: 1563 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?
Muhsen Al-ani¹, Bobby Kwanghoon Han ² and Gregory c Gardner ³, ¹University of Washington, seattle, WA, ²University of Washington, seattle, ³University of Wasshington, seattle
Background/Purpose: Systemic lupus erythematosus (SLE) is a disease with a variety of clinical manifestations but interestingly interstitial lung disease (ILD) is rare. The literature to…
Abstract Number: 2155 • 2019 ACR/ARP Annual Meeting
The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation
Sara Remuzgo-Martínez¹, Diana Prieto-Peña ², Mónica Calderón-Goercke ², Victor Manuel Mora Cuesta ³, David Iturbe Fernández ¹, Sonia M. Fernández Rozas ³, Jose Manuel Cifrian Martínez ³ and Miguel Angel González-Gay ⁴, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Rheumatology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ³Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL; and Pneumology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁴Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) occurs in approximately 15% of patients with autoimmune diseases (AD) [1]. Its presence is associated with an increased risk of…
Abstract Number: 189 • 2019 ACR/ARP Annual Meeting
Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Soo-Kyung Cho¹, Tracy J. Doyle ², Hemin Lee ³, Yinzhu Jin ³, Angela Y. Tong ³, Adrian J. Santiago Ortiz ³, Jeffrey Sparks ⁴ and Seoyoung C. Kim ³, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²Brigham and Women's Hospital, Harvard Medical School, Boston, ³Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The prevalence of interstitial lung disease (ILD) among rheumatoid arthritis (RA) patient ranges between 5-10%. ILD leads to high morbidity and mortality in patients…
Abstract Number: 1628 • 2019 ACR/ARP Annual Meeting
Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom
Aryeh Fischer¹, Oliver Distler ², Dinesh Khanna ³, Yannick Allanore ⁴, Anna Maria Hoffmann-Vold ⁵, Gabriele Valentini ⁶, Toby Maher ⁷, Martin Aringer ⁸, Leslie Meng ⁹, Margarida Alves ¹⁰, Martina Gahlemann ¹¹, Manuel Quaresma ¹⁰ and Masataka Kuwana ¹², ¹University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁴Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, ⁷National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, ⁸Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ¹²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is a common and usually early manifestation of systemic sclerosis (SSc). Decline in lung function in patients with SSc-ILD is…
Abstract Number: 2298 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Disease Is Associated with Distinct Fine Specificities of Anti-Carbamylated Peptide/Protein Antibodies in Rheumatoid Arthritis
Raul Castellanos-Moreira¹, Sebastian Rodriguez-Garcia ², Virginia Ruiz-Esquide ³, Fernanda Hernández-González ⁴, Marcelo Sánchez ⁵, José Ramírez ⁶, Mariana Benegas ⁵, Carmen Lucena-Pozo ⁴, Carlos Agustí ⁴, Marc Boada ⁷, Odette Viñas ⁸, Estíbaliz Ruiz ⁸, Sergio Prieto-González ⁹, Jose Gomez-Puerta ¹, Jacobo Sellares ⁴, Juan Cañete ¹, Isabel Haro ¹⁰ and Raimon Sanmarti ¹, ¹Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁴Department of Pneumology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Department of Radiodiagnosis, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Department of Pathological Anatomy, Hospital Clínic, Barcelona, Barcelona, Spain, ⁷Department of Thoracic Surgery, Hospital Clínic, Barcelona, Barcelona, Spain, ⁸Department of Immunology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁹Department of Systemic Autoimmune Diseases Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁰Unit of Synthesis and Biomedical Applications of Peptides, IQAC CSIC, Barcelona, Barcelona, Spain
Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of rheumatoid arthritis (RA). It has been associated with the presence of ACPA. Anti-carbamylated…
Abstract Number: 369 • 2019 ACR/ARP Annual Meeting
Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review
Esteban Rubio¹, Alejandro Muñoz ¹ and Núria Casamira ², ¹Rheumatology Department, University Hospital Virgen del Rocío, Sevilla, Spain, ²Medical Department, Gebro Pharma S.A., Barcelona, Spain
Background/Purpose: Methotrexate (MTX) is a commonly used drug for inflammatory joint diseases. Occasionally, its use has been associated with diffuse interstitial lung disease (DILD) development1. A…
Abstract Number: 1636 • 2019 ACR/ARP Annual Meeting
Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial
Maureen Mayes¹, Kristin Highland ², Martina Gahlemann ³, Aryeh Fischer ⁴, Ganesh Raghu ⁵, Mannaig Girard ⁶, Margarida Alves ⁷, Susanne Stowasser ⁷, Jörg Distler ⁸, Marco Matucci-Cerinic ⁹, Elizabeth Volkmann ¹⁰, Masataka Kuwana ¹¹ and Oliver Distler ¹², ¹Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁵University of Washington, Seattle, USA, Seattle, ⁶Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁹University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ¹⁰University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ¹¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: The presence of anti-topoisomerase I antibody (ATA) in patients with systemic sclerosis (SSc) has been associated with a greater risk of developing interstitial lung…
Abstract Number: 2339 • 2019 ACR/ARP Annual Meeting
Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-AssociatedInterstitial Lung Disease: Something to Keep in Mind
Sebastian Rodriguez-Garcia¹, Raul Castellanos-Moreira ², Fernanda Hernández-González ³, Albert Perez ⁴, Joel Francesqui ⁵, Sandra Cuerpo-Cardeñosa ⁵, Virginia Ruiz-Esquide ⁶, Mariana Benegas ⁷, José Ramírez ⁸, Carmen Lucena-Pozo ³, Carlos Agustí ³, Marc Boada ⁹, Estíbaliz Ruiz ⁴, Odette Viñas ⁴, Sergio Prieto-González ¹⁰, Raimon Sanmarti ¹¹, Gerard Espinosa ¹², Mariona Pascal ¹³, Jose Gomez-Puerta ¹¹, Marcelo Sánchez ⁷ and Jacobo Sellares ³, ¹Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ³Department of Pneumology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁴Department of Immunology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁵Pneumology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁶Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁷Department of Radiodiagnosis, Hospital Clínic, Barcelona, Barcelona, Spain, ⁸Department of Pathological Anatomy, Hospital Clínic, Barcelona, Barcelona, Spain, ⁹Department of Thoracic Surgery, Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁰Department of Systemic Autoimmune Diseases Hospital Clínic, Barcelona, Barcelona, Spain, ¹¹Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ¹²Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ¹³Immunology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain
Background/Purpose: Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is an extra-articular manifestation with a poor prognosis. In clinical practice, to establish such a diagnosis requires…
Abstract Number: 370 • 2019 ACR/ARP Annual Meeting
Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features
Sogol Amjadi¹, Tracy Frech ², Jessica Chan ³, Mary Beth Scholand ⁴, Troy Jaskowski ⁵, Sonia La’ulu ⁵, Jonathan Genzen ⁶, Dorota Lebiedz-Odrobina ⁷ and Ann Tebo ⁶, ¹University of Utah, Department of Internal Medicine, Division of Rheumatology, West Jordan, UT, ²Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ³University of Utah, Department of Radiology, salt lake city, UT, ⁴University of Utah, Department of Internal Medicine, Division of Pulmonary Medicine, salt lake city, UT, ⁵ARUP Institute for Clinical and Experimental Pathology, salt lake city, UT, ⁶ARUP Institute for Clinical and Experimental Pathology , University of Utah, Department of Pathology, salt lake city, UT, ⁷University of Utah, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Fibrotic lung diseases encompass a wide spectrum of clinical entities including connective tissue disease related interstitial lung disease (CTD-ILD) and interstitial pneumonia with autoimmune…
Abstract Number: 1643 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use
Madelon Vonk¹, Oliver Distler ², Daniel Furst ³, Eric Hachulla ⁴, Sindhu Johnson ⁵, Shervin Assassi ⁶, Leslie Meng ⁷, Manuel Quaresma ⁸, Margarida Alves ⁸, Emmanuelle Clerisme-Beaty ⁸ and Wim Wuyts ⁹, ¹Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, ²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ³University of California, Los Angeles, CA, ⁴Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, ⁵Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁹Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium
Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC)…
Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting
Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis
Takeshi Shoda¹, Tohru Takeuchi ², Takuya Kotani ², Koji Nagai ², Kennichiro Hata ², Shigeki Makino ² and Shigeki Arawaka ², ¹Yodogawa christian hospital / Osaka medical college, Osaka, Japan, ²Osaka medical college, Osaka, Japan
Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…
Abstract Number: 374 • 2019 ACR/ARP Annual Meeting
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Eric Matteson¹, Clive Kelly ², Jörg Distler ³, Anna Maria Hoffmann-Vold ⁴, James Seibold ⁵, Shikha Mittoo ⁶, Oliver Distler ⁷, Rainer-Georg Goeldner ⁸, Rozsa Schlenker-Herceg ⁹, Susanne Stowasser ¹⁰, Manuel Quaresma ¹⁰ and Kevin Flaherty ¹¹, ¹Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ²Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK, Newcastle, United Kingdom, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁵Scleroderma Research Consultants LLC, Aiken, South Carolina, USA, Aiken, ⁶University Health Network, Toronto, Ontario, Canada, Toronto, Canada, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁸Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany, ⁹Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, ¹⁰Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹¹University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Some patients with autoimmune disease develop progressive fibrosing interstitial lung disease (ILD) characterized by increasing fibrosis on HRCT, decline in lung function, worsening symptoms…
Abstract Number: 1644 • 2019 ACR/ARP Annual Meeting
Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial
Masataka Kuwana¹, Kristin Highland ², Martina Gahlemann ³, Christopher Denton ⁴, Aryeh Fischer ⁵, Maureen Mayes ⁶, Virginia Steen ⁷, Dinesh Khanna ⁸, Yannick Allanore ⁹, Mannaig Girard ¹⁰, Margarida Alves ¹¹, Susanne Stowasser ¹¹ and Oliver Distler ¹², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ²Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ³Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, ⁴University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom, ⁵University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, ⁶Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, ⁷Georgetown University, Washington, D.C., USA, Georgetown, ⁸Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ⁹Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ¹⁰Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, ¹¹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹²Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Patients with diffuse cutaneous systemic sclerosis (dcSSc) are at greater risk of developing interstitial lung disease (ILD) than patients with limited cutaneous systemic sclerosis…
Abstract Number: 2341 • 2019 ACR/ARP Annual Meeting
Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease
Scott Matson¹, Kevin Deane ², Christopher Collora ¹, Xi Zheng ¹, Marie Fester ¹, Joyce Lee ¹ and M. Kristen Demoruelle ³, ¹University of Colorado, Denver, ²University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, ³University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora
Background/Purpose: Pulmonary manifestations of rheumatoid arthritis (RA) lead to significant morbidity and mortality. Lung manifestations in RA are myriad, however little is known about how…